title: The effect of repeated administration of methotrexate (MTX) on rat ovary: measurement of serum antimullerian hormone (AMH) levels.
abstract: OBJECTIVE
  To evaluate the possible effect of methotrexate (MTX) on rat ovaries by measuring serum antimullerian hormone (AMH), the novel marker of the ovarian reserve.
  
  
  METHODS
  Pretreatment serum AMH levels were measured in 15 Wistar albino rats. MTX was given in 1 mg/kg dose in days 1, 3, 5, and 7. Serum AMH levels were measured twenty-four hours after each MTX administration. Pre- and post-treatment serum AMH levels were compared.
  
  
  RESULTS
  Pretreatment median serum AMH was 102.4 ng/mL (25%: 41.9; 75%: 179.8). The median serum AMH levels were 70.6 ng/mL (25%: 54.08; 75%: 125.5); 136.1 ng/mL (25%: 57.3; 75%: 223.09); 121.2 ng/mL (25%: 52.5; 75%: 151.5); and 104.7 ng/mL (25%: 65.8; 75%: 265.5) after the first, second, third, and fourth methotrexate administrations, respectively. The ratio of the final (eighth day) median serum AMH level to the pretreatment median AMH level was 1.27 (25%: 0.84 and 75%: 2.57). Wilcoxon related samples test showed that final AMH was significantly higher as compared to the second day AMH measurement (p = 0.041).
  
  
  CONCLUSIONS
  MTX administration did not cause a statistically significant change between pretreatment and final serum AMH levels in rats. There was no decrease in AMH levels indicating a decrease in ovarian reserve.
authors: Department of Obstetrics and Gynecology, Cerrahpasa School of Medicine, Istanbul University, Istanbul, Turkey. abenian@hotmail.com
authors: Ali
authors: A
authors: Benian
authors: Onur
authors: O
authors: Guralp
authors: Duygu Derya
authors: DD
authors: Uzun
authors: Alper
authors: A
authors: Okyar
authors: Sezai
authors: S
authors: Sahmay
mesh_terms: D000818:Animals; D054304:Anti-Mullerian Hormone / Q000097:blood*; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000009:adverse effects; D015415:Biomarkers / Q000097:blood; D004305:Dose-Response Relationship, Drug; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects; D008727:Methotrexate / Q000008:administration & dosage* / Q000009:adverse effects; D019384:Nucleic Acid Synthesis Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D010053:Ovary / Q000187:drug effects*; D016649:Primary Ovarian Insufficiency / Q000097:blood / Q000139:chemically induced*; D051381:Rats; D017208:Rats, Wistar; D015203:Reproducibility of Results
chemical_list: D000964:Antimetabolites, Antineoplastic; D018501:Antirheumatic Agents; D015415:Biomarkers; D007166:Immunosuppressive Agents; D019384:Nucleic Acid Synthesis Inhibitors; D054304:Anti-Mullerian Hormone; D008727:Methotrexate